Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: alvarez i. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. Among authors: alvarez i, alvarez jv. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A. González A, et al. Among authors: alvarez i. Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Clin Transl Oncol. 2017. PMID: 27853985 Review.
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M. Llombart-Cussac A, et al. Among authors: alvarez i. Cancer. 2012 Jan 1;118(1):241-7. doi: 10.1002/cncr.26299. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717449 Free article. Clinical Trial.
Advanced breast cancer: chemotherapy phase III trials that change a standard.
Estevez LG, Tusquets I, Muñoz M, Adrover E, Rovira PS, Seguí MA, Rodríguez CA, Lescure AR, Ruiz M, Alvarez I, Mata JG. Estevez LG, et al. Among authors: alvarez i. Anticancer Drugs. 2007 Aug;18(7):843-59. doi: 10.1097/CAD.0b013e3280bad81a. Anticancer Drugs. 2007. PMID: 17581310
Supportive care for patients with early breast cancer.
García-Estévez L, Tusquets I, Alvarez I, Rodríguez C, Fernández Y, Seguí MA, García-Mata J, Lluch A. García-Estévez L, et al. Among authors: alvarez i. Clin Transl Oncol. 2010 Jan;12(1):32-42. doi: 10.1007/s12094-010-0464-1. Clin Transl Oncol. 2010. PMID: 20080469 Review.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Martín M, et al. Among authors: alvarez i. J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733779 Clinical Trial.
796 results